Precision BioSciences, Inc. (NASDAQ:DTIL) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have received a consensus rating of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $32.25.

DTIL has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a report on Wednesday, May 27th. Wall Street Zen upgraded Precision BioSciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. JonesTrading reaffirmed a “buy” rating and set a $30.00 price objective on shares of Precision BioSciences in a report on Friday, April 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $19.00 target price on shares of Precision BioSciences in a research note on Friday, March 13th. Finally, Weiss Ratings upgraded shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $8.18 on Friday. The stock has a market cap of $211.04 million, a price-to-earnings ratio of -2.23 and a beta of 1.25. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. Precision BioSciences has a fifty-two week low of $3.53 and a fifty-two week high of $8.82. The firm’s 50-day simple moving average is $7.13 and its 200 day simple moving average is $5.71.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The company had revenue of $10.84 million during the quarter, compared to analysts’ expectations of $4.05 million. As a group, research analysts anticipate that Precision BioSciences will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Precision BioSciences

Several hedge funds have recently modified their holdings of the company. Aberdeen Group plc purchased a new position in shares of Precision BioSciences in the 4th quarter worth approximately $8,897,000. Empery Asset Management LP purchased a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $9,130,000. HBK Sorce Advisory LLC bought a new stake in Precision BioSciences during the fourth quarter worth $38,000. Quantinno Capital Management LP bought a new stake in Precision BioSciences during the first quarter worth $104,000. Finally, Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences in the fourth quarter worth $52,000. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.